Press Releases

Dosing in Phase I PK study for EMPLI03 completed

Emplicure AB today reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain

Emplicure today reported dosing in the first pharmacokinetic study with EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine. Safety and tolerability were followed, and the subjects could leave the clinic after completion of the study as planned. Top line data will be available in the beginning of 2023.

The Emplicure group is developing innovative consumer and pharmaceutical products based on its proprietary bioceramic technology platform, Emplior.

EMPLI03 is being developed as an oral buccal tablet with extended release properties intended for the treatment of moderate to severe pain. The formulation is also designed to limit the potential for manipulation of the tablet for abuse. Supported by its Translational Pharmaceutics® platform Quotient Sciences has established the GMP manufacturing process of EMPLI03 and performed this first pharmacokinetic study for Emplicure.

"We have achieved one of our milestones in the development of a Buprenorphine product for the treatment of moderate to severe pain. With properties that limit abuse, EMPLI03 may contribute to a safer medical treatment", said Håkan Engqvist, CEO of Emplicure.

Pain is a major health issue globally and, in the US, as many as 20% of the population is estimated to suffer from chronic pain and in need of long-term pain relief. Widespread moderate to severe pain is a problem that is associated with high costs for society and individual patients. Opioids are, and will continue to be, an important part of pain treatment.

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: erik.magnusson@emplicure.com

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

2023-06-05
Regulatory

The board of directors of Emplicure AB (publ) ("Emplicure" or the "Company") recommends the shareholders of Emplicure not to accept the mandatory takeover offer of SEK 0.50 per share made by TomEQT Private AB ("TomEQT Private") on May 29, 2023.

2023-05-29
Regulatory

TomEQT Private AB ("TomEQT Private") has today announced a mandatory takeover offer in cash for the shares in Emplicure AB (publ) ("Emplicure" or the "Company") at a price of SEK 0.50 per share (the "Offer"). The Offer is made in accordance with the rules regarding mandatory takeover offers since TomEQT Private's shareholding in Emplicure, following the directed issue of shares resolved by the board of directors of Emplicure on 24 May 2023, now amounts to approximately 50.6 percent of the total number of shares and votes in Emplicure.

2023-05-24
Regulatory

The board of directors of Emplicure AB (publ) ("Emplicure" or the "Company") has today, as authorised by the general meeting on 2 May 2023, resolved on a directed issue of 50,000,000 new shares through which the Company receives 25,000,000 SEK before issue costs (the "Directed Issue"). The right to subscribe for shares in the Directed Issue shall, with deviation from the shareholders pre-emption rights, belong to TomEQT Private AB (the "Investor"). The subscription price in the Directed Issue is 0.50 SEK per share and has been determined after negotiations with the Investor. The reason for the deviation from the shareholders' pre-emption rights is that the board of directors, in an overall assessment and after careful consideration, considers that a directed issue to the Investor is the preferred alternative to meet the Company's capital needs and that it is objectively in the interest of both the Company and its shareholders to carry out the Directed Issue. The board of directors has carefully considered the possibility of carrying out a rights issue to raise the required capital but deemed that it would be more time-consuming and entail significantly higher costs and an increased market risk exposure. Through the Directed Issue, the Investor will reach a shareholding of approximately 50.6 percent of the outstanding shares and votes in the Company entailing that the mandatory bid threshold will be exceeded. The Investor has notified the board of directors that the Investor intends to fulfil its mandatory bid obligation and make a public takeover offer regarding the remaining shares in the Company.

2023-05-23
Regulatory

The 2022 Annual report of Emplicure AB (publ) is now available on the Company's website.

2023-05-11
Regulatory

The shareholders in Emplicure AB (publ) reg. no. 556967-7189 (the "Company") are hereby given notice that the Annual General Meeting will be held on Tuesday 13 June 2023, at 2.00 p.m. at the law firm Lindahl's premises, Vaksalagatan 10, Uppsala, Sweden. Registration starts at 1.45 p.m. and will stop when the meeting starts.

2023-05-09
Regulatory
2023-05-02
Regulatory

The extra general meeting in Emplicure AB (publ), corp. reg. no 556967-7189 (the "Company") was held on 2 May 2023 in Uppsala whereby the shareholders primarily resolved on the following matters.

2023-04-21

Amplicon är glada över att kunna presentera Småå, ett helt nytt koncept inom vita, tobaksfria nikotinpåsar som förhöjer upplevelsen för konsumenten. Innehållet i Småås påsar utformas med patenterad biokeramisk teknik som gör det möjligt att erbjuda riktigt små påsar med betydligt längre smak- och nikotinupplevelse.

1
2
...
9
>>

Do you want to know more?